Amgen, UCB say osteoporosis drug meets main goal in late-stage trial

(Reuters) - Amgen Inc and Belgium-based UCB SA said on Monday that their osteoporosis drug met all the primary endpoints by reducing the incidence of new vertebral fracture in postmenopausal women with osteoporosis in a late-stage study.

http://ift.tt/1Q4AH7A

from Reuters: Health News
via animenewspro